FibroGen, Inc.
http://www.fibrogen.com
Already a Biomedtracker subscriber?
You have access to the full company record through your subscription
Want to become a subscriber?
Subscribers get more company details, updates, company financials and company products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From FibroGen, Inc.
Medicare Bundled Payment Policies Could Cut Amgen’s Parsabiv Sales By 50%
Amgen ‘looks forward’ to working with CMS and Congress to shape Medicare reimbursement policies in a way that better ensures access.
AZ Brushes Off Vaccine Criticism, Awaits US Readout
While fast-developing news on COVID-19 is grabbing the headlines, oncology will continue to drive growth in 2021.
Watching The Review Clock: Are US FDA Goal Date Extensions Reason For Optimism?
Novel agents that received three-month user fee goal date extensions have a slightly higher approval rate than novel applications overall.
China Approves Record New Cancer, Orphan Drugs In 2020 But Access Challenges Remain
Throughout 2020, China’s drive to introduce more and newer drugs to the market did not slow but was rather accelerated by the COVID-19 pandemic. But can people afford them?
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
-
Medical Devices
- Biomaterials
- Other Names / Subsidiaries
-
- FibroGen China Anemia Holdings Ltd.
- FibroGen (China) Medical Technology Development Co., Ltd.
- FibroGen Europe Oy
- FibroGen International (Cayman) Limited
- FibroGen International (Hong Kong) Limited
- Skin Sciences, Inc.